Cardior Pharmaceuticals GmbH

Based in Germany, Cardior Pharmaceuticals GmbH specializes in developing RNA-based therapeutics to combat heart disease, focusing on innovative solutions for cardiac care. Established in 2016 and headquartered in Hannover, Germany, Cardior Pharmaceuticals GmbH is dedicated to developing RNA-based treatments targeting heart disease. The company has completed 5 investment deals and has been active in scaling its operations since its inception. Thomas Thum, the founder, has a background in medical research, further bolstering the company's innovative endeavors.

As of March 25, 2024, Cardior Pharmaceuticals underwent a TRADE SALE, raising EUR 1. 025 bn in total, which marks a pivotal moment in its business trajectory. Cardior Pharmaceuticals specializes in the development of RNA-based therapeutics, with a primary focus on non-coding RNAs aimed at addressing heart disease's underlying causes. The core product, CDR132L, operates within cardiac cells to reverse adverse cardiac remodeling and restore normal functions, currently undergoing evaluation in the HF-REVERT Phase 2 Clinical Study.

This therapeutic approach seeks to meet the essential clinical needs of heart failure patients, particularly those recovering from myocardial infarction, thus targeting a global patient demographic across Europe and North America. Cardior Pharmaceuticals generates revenue primarily through clinical partnerships and collaborations aimed at developing and commercializing its lead product, CDR132L. The revenue model is structured around strategic partnerships that advance their RNA-based therapeutics through various clinical phases, with potential milestones and licensing agreements providing avenues for shared investment and profit as they prepare for market entry once clinical efficacy is established. For the year 2021, the company's EBITDA was EUR -9,070,481.

4. In March 2024, Novo Nordisk A/S agreed to acquire Cardior Pharmaceuticals GmbH for EUR 1. 03 billion, which is intended to enhance Novo Nordisk's capabilities in developing projects focused on cardiovascular diseases. The acquisition will provide the necessary resources to support Cardior's ongoing research and development efforts, particularly regarding the launch of CDR132L and potential expansion into additional markets, specifically targeting regions with high demand for effective cardiac therapies by the end of 2025.